Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentation

Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults With Severe Hemophilia A

Download PDF